ATE19792T1 - Verfahren zur herstellung eines kolonspezifischen antigen p tryptischen peptides und von anti-kolon-spezifischen antigen p antikoerpern. - Google Patents

Verfahren zur herstellung eines kolonspezifischen antigen p tryptischen peptides und von anti-kolon-spezifischen antigen p antikoerpern.

Info

Publication number
ATE19792T1
ATE19792T1 AT82104604T AT82104604T ATE19792T1 AT E19792 T1 ATE19792 T1 AT E19792T1 AT 82104604 T AT82104604 T AT 82104604T AT 82104604 T AT82104604 T AT 82104604T AT E19792 T1 ATE19792 T1 AT E19792T1
Authority
AT
Austria
Prior art keywords
colon
specific antigen
antibodies
tryptic peptide
production
Prior art date
Application number
AT82104604T
Other languages
English (en)
Inventor
Milton David Goldenberg
Dan Shochat
Original Assignee
Milton David Goldenberg
Dan Shochat
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Milton David Goldenberg, Dan Shochat filed Critical Milton David Goldenberg
Application granted granted Critical
Publication of ATE19792T1 publication Critical patent/ATE19792T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57446—Specifically defined cancers of stomach or intestine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT82104604T 1981-06-01 1982-05-27 Verfahren zur herstellung eines kolonspezifischen antigen p tryptischen peptides und von anti-kolon-spezifischen antigen p antikoerpern. ATE19792T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US06/269,115 US4468457A (en) 1981-06-01 1981-06-01 Method for producing a CSAp tryptic peptide and anti-CSAp antibodies
EP82104604A EP0066786B1 (de) 1981-06-01 1982-05-27 Verfahren zur Herstellung eines Kolon-spezifischen Antigen P tryptischen Peptides und von anti-Kolon-spezifischen Antigen P Antikörpern

Publications (1)

Publication Number Publication Date
ATE19792T1 true ATE19792T1 (de) 1986-05-15

Family

ID=23025864

Family Applications (1)

Application Number Title Priority Date Filing Date
AT82104604T ATE19792T1 (de) 1981-06-01 1982-05-27 Verfahren zur herstellung eines kolonspezifischen antigen p tryptischen peptides und von anti-kolon-spezifischen antigen p antikoerpern.

Country Status (9)

Country Link
US (1) US4468457A (de)
EP (1) EP0066786B1 (de)
JP (1) JPS58501355A (de)
AT (1) ATE19792T1 (de)
AU (1) AU550306B2 (de)
CA (1) CA1183451A (de)
DE (1) DE3271119D1 (de)
IL (1) IL65915A (de)
WO (1) WO1982004263A1 (de)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4472509A (en) * 1982-06-07 1984-09-18 Gansow Otto A Metal chelate conjugated monoclonal antibodies
US4454106A (en) * 1982-06-07 1984-06-12 Gansow Otto A Use of metal chelate conjugated monoclonal antibodies
DE3432714A1 (de) * 1984-09-06 1986-04-24 Behringwerke Ag, 3550 Marburg Tumortherapeutikum und verfahren zu seiner herstellung
US4962187A (en) * 1984-11-28 1990-10-09 Cota Biotech Common antigen for colorectal and mucinous ovarian tumors and process for isolating the same
ES8800604A1 (es) * 1985-04-22 1987-11-16 Hybritech Inc Un metodo para producir anticuerpos monoclonales
DK172686A (da) * 1985-04-22 1986-10-23 Hybritech Inc Antigen opnaaet ud fra humant vaev, fremgangsmaade til under anvendelse af antigenet at fremstille monoklonale antistoffer til diagnose og behandling af cancer, fremgangsmaade til paavisning af cancer, samt antistoffer mod antigenet
US5776093A (en) * 1985-07-05 1998-07-07 Immunomedics, Inc. Method for imaging and treating organs and tissues
DK169987D0 (da) * 1987-04-03 1987-04-03 Jens Christian Jensenius Human tumor-associated antigen, ca-ou1
CA1329119C (en) * 1988-03-29 1994-05-03 Milton David Goldenberg Cytotoxic therapy
EP0721345B1 (de) * 1993-08-11 2005-08-31 Jenner Technologies Impfstoff gegen prostatakrebs
US7011812B1 (en) 1996-05-03 2006-03-14 Immunomedics, Inc. Targeted combination immunotherapy of cancer and infectious diseases
US6759243B2 (en) 1998-01-20 2004-07-06 Board Of Trustees Of The University Of Illinois High affinity TCR proteins and methods
DE69942565D1 (de) * 1998-05-20 2010-08-19 Immunomedics Inc Therapeutische mittel welche einen bispezifischen anti-hla class ii invariant chain x anti-pathogen antikörper enthalten
US7405320B2 (en) 1998-06-22 2008-07-29 Immunomedics, Inc. Therapeutic and diagnostic conjugates for use with multispecific antibodies
US7833528B2 (en) * 1998-06-22 2010-11-16 Immunomedics, Inc. Use of multispecific, non-covalent complexes for targeted delivery of therapeutics
US7387772B1 (en) * 1999-06-22 2008-06-17 Immunimedics, Inc. Chimeric, human and humanized anti-CSAP monoclonal antibodies
US6962702B2 (en) * 1998-06-22 2005-11-08 Immunomedics Inc. Production and use of novel peptide-based agents for use with bi-specific antibodies
US7138103B2 (en) * 1998-06-22 2006-11-21 Immunomedics, Inc. Use of bi-specific antibodies for pre-targeting diagnosis and therapy
US6361774B1 (en) * 1999-09-17 2002-03-26 Immunomedics, Inc. Methods and compositions for increasing the target-specific toxicity of a chemotherapy drug
JP4972264B2 (ja) 1999-12-06 2012-07-11 ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ イリノイ 高親和性ｔｃｒタンパク質および方法
US7897140B2 (en) 1999-12-23 2011-03-01 Health Research, Inc. Multi DTPA conjugated tetrapyrollic compounds for phototherapeutic contrast agents
EP1351712B1 (de) * 2000-06-20 2007-08-01 Immunomedics, Inc. Zielgerichtete kombinationsimmuntherapie für krebs und infektionskrankheiten
AU2002220275A1 (en) * 2000-12-08 2002-06-18 The Board Of Trustees Of The University Of Illinois Mutated class ii major histocompatibility proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
DE60213771T2 (de) * 2001-03-30 2007-08-16 The University of Massachusetts, Worcester Morpholinobildgebung und therapie
US8877901B2 (en) 2002-12-13 2014-11-04 Immunomedics, Inc. Camptothecin-binding moiety conjugates
US7591994B2 (en) 2002-12-13 2009-09-22 Immunomedics, Inc. Camptothecin-binding moiety conjugates
EP1517684B1 (de) 2002-06-27 2009-07-22 Health Research, Inc. Fluorinierte chlorin und bacteriochlorin photosensitizer für fotodynamische therapie
WO2004005289A2 (en) 2002-07-02 2004-01-15 Health Research, Inc. Efficient synthesis of pyropheophorbide a and its derivatives
US20060024289A1 (en) * 2002-10-02 2006-02-02 Ruggles Sandra W Cleavage of VEGF and VEGF receptor by wild-type and mutant proteases
US7939304B2 (en) * 2002-10-02 2011-05-10 Catalyst Biosciences, Inc. Mutant MT-SP1 proteases with altered substrate specificity or activity
ATE517638T1 (de) 2003-01-31 2011-08-15 Immunomedics Inc Verfahren und zubereitungen zum verabreichen von therapeutischen und diagnostischen mitteln
US7057100B2 (en) * 2003-06-26 2006-06-06 The J.C. Robinson Seed Co. Inbred corn line W23129
WO2005086612A2 (en) * 2003-07-29 2005-09-22 Immunomedics, Inc. Fluorinated carbohydrate conjugates
CN101501211A (zh) 2004-03-31 2009-08-05 综合医院公司 测定癌症对表皮生长因子受体靶向性治疗反应性的方法
AU2005244271B2 (en) 2004-04-12 2010-04-08 Vertex Pharmaceuticals Incorporated Cleavage of VEGF and VEGF receptor by wildtype and mutant MT-SP1
US20050260131A1 (en) * 2004-05-20 2005-11-24 General Electric Company Pharmaceuticals for enhanced delivery to disease targets
PT2298815E (pt) 2005-07-25 2015-07-16 Emergent Product Dev Seattle Moléculas de ligaçao especificas para cd37 e especificas para cd20
EP2674440B1 (de) 2005-12-16 2019-07-03 IBC Pharmaceuticals, Inc. Polyvalente bioaktive anordnungen auf immunglobulinbasis
CA3149553C (en) 2006-06-12 2023-11-21 Aptevo Research And Development Llc Single-chain multivalent binding proteins with effector function
DK2046951T5 (da) 2006-07-05 2012-01-23 Catalyst Biosciences Inc Proteasesreeningsmetoder og proteaser identificeret dermed
CA2719924C (en) 2008-04-11 2017-10-03 Philip Tan Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
DK3903829T3 (da) 2009-02-13 2023-06-26 Immunomedics Inc Immunkonjugater med en intracellulær spaltelig binding
US8012770B2 (en) 2009-07-31 2011-09-06 Invisible Sentinel, Inc. Device for detection of antigens and uses thereof
US9475049B2 (en) 2009-07-31 2016-10-25 Invisible Sentinel, Inc. Analyte detection devices, multiplex and tabletop devices for detection of analyte, and uses thereof
CA2777053A1 (en) 2009-10-06 2011-04-14 The Board Of Trustees Of The University Of Illinois Human single-chain t cell receptors
EP2486120B1 (de) 2009-10-09 2014-04-02 Invisible Sentinel, Inc. Vorrichtung zum nachweis von antigenen und anwendungen davon
US9745631B2 (en) 2011-12-20 2017-08-29 Dana-Farber Cancer Institute, Inc. Methods for diagnosing and treating oncogenic kras-associated cancer
EP3578980B1 (de) 2012-03-09 2021-09-15 Invisible Sentinel, Inc. Verfahren und zusammensetzungen zur erkennung von mehreren analyten mit einem einzigen signal
CA2874521A1 (en) 2012-05-24 2013-11-28 Dana-Farber Cancer Institute, Inc. Targeting the glutamine to pyruvate pathway for treatment of oncogenic kras-associated cancer
US20150285802A1 (en) 2012-07-18 2015-10-08 Dana-Farber Cancer Institute, Inc. Methods for treating, preventing and predicting risk of developing breast cancer
JP6433894B2 (ja) 2012-07-27 2018-12-05 ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ イリノイ Ｔ細胞受容体の操作
EP2885002A4 (de) 2012-08-14 2016-04-20 Ibc Pharmaceuticals Inc Umleitung t-zell-bispezifischer antikörper zur behandlung von krankheiten
CA3177936A1 (en) 2012-12-13 2014-06-19 Immunomedics, Inc. Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
WO2014124307A2 (en) 2013-02-08 2014-08-14 The Regents Of The University Of Michigan Targeted theranostics
US9932623B2 (en) 2013-08-19 2018-04-03 Abbott Molecular Inc. Nucleotide analogs
WO2015050844A1 (en) 2013-10-01 2015-04-09 Dana-Farber Cancer Institute, Inc. Methods of treating cancer with atovaquone-related compounds
CA2930847A1 (en) 2013-11-22 2015-05-28 Fred Hutchinson Cancer Research Center Engineered high-affinity human t cell receptors
US10350264B2 (en) 2014-03-27 2019-07-16 Dana-Farber Cancer Institute, Inc. Compositions and methods for modulating NCOA4-mediated autophagic targeting of ferritin
JP6841772B2 (ja) 2015-02-17 2021-03-10 エラスムス・ユニヴァーシティ・メディカル・センター・ロッテルダム 前立腺癌の処置におけるカバジタキセルの使用
SI3316885T1 (sl) 2015-07-01 2021-09-30 Immunomedics, Inc. Imunokonjugati protitelo-SN-38 z linkerjem CL2A
UA126278C2 (uk) 2015-09-21 2022-09-14 Аптево Рісьорч Енд Девелопмент Ллс Поліпептиди, які зв'язують cd3
WO2017151836A1 (en) 2016-03-04 2017-09-08 East Carolina University J-series prostaglandin-ethanolamides as novel therapeutics for skin and/or oral disorders
US10919904B2 (en) 2016-08-17 2021-02-16 North Carolina State University Northern-southern route to synthesis of bacteriochlorins
WO2018102252A1 (en) 2016-11-30 2018-06-07 North Carolina State University Methods for making bacteriochlorin macrocycles comprising an annulated isocyclic ring and related compounds
EP3675866B1 (de) 2017-09-01 2023-08-02 East Carolina University Ex vivo verfahren zur aktivierung von immunzellen
WO2020236818A1 (en) 2019-05-20 2020-11-26 Nirvana Sciences Inc. Narrow emission dyes, compositions comprising same, and methods for making and using same

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2719102A (en) * 1949-10-28 1955-09-27 Corn States Serum Company Clostridium perfringens toxoid and process of making the same
US4086217A (en) * 1976-03-03 1978-04-25 Hoffmann-La Roche Inc. Carcinoembryonic antigens
US4228236A (en) * 1978-05-15 1980-10-14 Northwestern University Process of producing carcinoembryonic antigen

Also Published As

Publication number Publication date
WO1982004263A1 (en) 1982-12-09
AU550306B2 (en) 1986-03-13
EP0066786A2 (de) 1982-12-15
EP0066786B1 (de) 1986-05-14
IL65915A0 (en) 1982-08-31
US4468457A (en) 1984-08-28
JPS58501355A (ja) 1983-08-18
AU8731882A (en) 1982-12-07
EP0066786A3 (en) 1983-07-20
CA1183451A (en) 1985-03-05
DE3271119D1 (en) 1986-06-19
IL65915A (en) 1985-07-31

Similar Documents

Publication Publication Date Title
ATE19792T1 (de) Verfahren zur herstellung eines kolonspezifischen antigen p tryptischen peptides und von anti-kolon-spezifischen antigen p antikoerpern.
KR900009095A (ko) 합성 항원, 이의 제조방법 및 용도
ES8305419A1 (es) Un peptido
DK0461177T3 (da) Humant intra-acrosomalt spermantigen til anvendelse i en svangerskabsforebyggende vaccine
AU1130392A (en) Synthetic htlv-iii peptides, compositions and uses thereof
SE8205313L (sv) Antigen-proteinkomplex for blockering av allergiska reaktioner samt sett for framstellning derav
ATE138923T1 (de) Verfahren zur herstellung gereinigter glycolipide durch membrantrennverfahren
DE3788229D1 (de) Verfahren zur isolierung von ca 125-antigen.
KR840009069A (ko) 향정신성 펩티드류의 제조 방법
ATE5592T1 (de) Verfahren zur herstellung von 4'deoxydaunorubicin und 4'-deoxydoxorubicin, sowie 4'-epi-4'-trifluormethyl-sulfonyloxy-ntrifluoracetyldaunorubicin.
SE8103198L (sv) Forfarande for framstellning av antikroppar
DE69101281T2 (de) Tieftemperatur-Lufttrennung zur Erzeugung von druckerhöhtem Produktgas.
GB1375811A (de)
DE69738770D1 (de) Porphyromonas gingivalis Antigene zur Diagnose und Behandlung von Periodontitis
JPS5657753A (en) Novel glucagon fragment, and its use
AU612683B2 (en) Synthetic peptides, antibodies directed against them, and the use thereof
NO900758D0 (no) Fremgangsmaate for fremstilling av hybridprotein.
ATE91304T1 (de) Verfahren zur herstellung des pres 1/s2/shepatitis-b-antigens aus hefe.
KR840002346A (ko) 펩타이드의 제조방법
SU646162A1 (ru) Способ разделени природного и попутного газов
SU587977A1 (ru) Способ очистки газа от сероводорода
PT79232B (en) Process for producing immune interferon and of pharmaceutical compositions containing the same
JPS5344620A (en) Recovering of immobilized vaccine and specific antigen
NO921496L (no) Fremgangsmaate for fremstilling av et peptid eller proteinbeslektet med det melanomaforbundne p97-antigen
DE3475309D1 (en) Synthetic peptide, immune globulin and process for immunizing a mammal

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties